Therapeutic effect of PD-1 antibody on pancreatic cancer in mice
Objective To evaluate the therapeutic effect of PD-1 antibody in mouse with pancreatic carcinoma. Methods In situ and subcutaneous pancreatic cancer models were constructed by injecting pan 02 cells into 6-8week C57 mice. The C57 mice were randomly divided into two groups, the PD-1 antibody group and the observation group. PD-1 antibody group was injected intraperitoneally at 200 ug/mouse every 5 days for a total of 3 times, and the observation group was given equal volume of PBS. One week after treatment, size of tumor, number of CD8+cells, serum IFN-γ level, and survival time in the two groups were observed. Results Tumor weight in the two groups were (0.77±0.05)g and (1.44±0.07)g respectively (P<0.01). Number of CD8+T cells was (27.96±1.84) % and (19.38±1.15) % respectively in peripheral blood (P<0.01), and (34.80±3.29) % and (22.45±1.78) % respectively in tumor tissue. IFN-γ level also showed significant difference between the two groups, (39.01±3.08) pg/mL in the PD-1 group vs (15.78±2.26) pg/mL in the PBS group, P<0.01. Median survival time was 52.6 days (95% CI: 48.4-57.6) in the PD-1 antibody group, and 39.1 days (95% CI: 36.1-42.1) in the PBS group (P<0.01). Conclusion PD-1 antibody significantly increased number of CD8+T cells in both peripheral blood and tumor tissue, inhibited growth of in situ pancreatic cancer in mouse, and extended survival time.
PD-1 antibodypancreatic cancerCD8+T cellssurvival time
NETL
NSTL
万方数据
维普
